

SECOND REGULAR SESSION
[PERFECTED]
HOUSE COMMITTEE SUBSTITUTE FOR
HOUSE BILL NO. 1051
97TH GENERAL ASSEMBLY

4111H.02P

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to synthetic cannabinoids, with penalty provisions.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

- (1) Has high potential for abuse; and
- (2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

- (1) The controlled substances listed in this subsection are included in Schedule I;
- (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

- (a) Acetyl-alpha-methylfentanyl;
- (b) Acetylmethadol;
- (c) Allylprodine;
- (d) Alphacetylmethadol;
- (e) Alphameprodine;
- (f) Alphamethadol;
- (g) Alpha-methylfentanyl;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etoxidine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;

- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;
- 66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers
- 67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers
- 68 is possible within the specific chemical designation:
 - 69 (a) Acetorphine;
 - 70 (b) Acetyldihydrocodeine;
 - 71 (c) Benzylmorphine;
 - 72 (d) Codeine methylbromide;
 - 73 (e) Codeine-N-Oxide;
 - 74 (f) Cyprenorphine;
 - 75 (g) Desomorphine;
 - 76 (h) Dihydromorphine;
 - 77 (i) Drotebanol;
 - 78 (j) Etorphine (except hydrochloride salt);
 - 79 (k) Heroin;
 - 80 (l) Hydromorphenol;
 - 81 (m) Methyldesorphine;
 - 82 (n) Methyldihydromorphine;
 - 83 (o) Morphine methylbromide;
 - 84 (p) Morphine methylsulfonate;
 - 85 (q) Morphine-N-Oxide;
 - 86 (r) Myrophine;
 - 87 (s) Nicocodeine;
 - 88 (t) Nicomorphine;
 - 89 (u) Normorphine;

- (v) Pholcodine;
- (w) Thebacon;
- (4) Any material, compound, mixture or preparation which contains any quantity of the following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
- (a) 4-bromo-2, 5-dimethoxyamphetamine;
- (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- (c) 2,5-dimethoxyamphetamine;
- (d) 2,5-dimethoxy-4-ethylamphetamine;
- (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- (f) **2C-C or (2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine);**
- (g) **2C-D or (2-(2,5-Dimethoxy-4-methylphenyl) ethanamine);**
- (h) **2C-E or (2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine);**
- (i) **2C-H or (2-(2,5-Dimethoxyphenyl) ethanamine);**
- (j) **2C-I or (2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine);**
- (k) **2C-N or (2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine);**
- (l) **2C-P or (2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine);**
- (m) **2C-T-2 or (2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine);**
- (n) **2C-T-4 or (2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine);**
- (o) **2C-T-7 or 2,5-dimethoxy-4-(n)-propylthiophenethylamine;**
- (p) **2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);**
- (q) **2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);**
- (r) **2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);**
- (s) 4-methoxyamphetamine;
- [(g)] (t) 5-methoxy-3,4-methylenedioxyamphetamine;
- [(h)] (u) 4-methyl-2, 5-dimethoxyamphetamine;
- [(i)] (v) 3,4-methylenedioxyamphetamine;
- [(j)] (w) 3,4-methylenedioxymethamphetamine;
- [(k)] (x) 3,4-methylenedioxy-N-ethylamphetamine;
- [(l)] (y) N-hydroxy-3, 4-methylenedioxyamphetamine;
- [(m)] (z) 3,4,5-trimethoxyamphetamine;

- 125 [(n)] **(aa)** 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and
126 salts of isomers;
- 127 [(o)] **(bb)** Alpha-ethyltryptamine;
- 128 [(p)] **(cc)** Alpha-methyltryptamine;
- 129 [(q)] **(dd)** Bufotenine;
- 130 [(r)] **(ee)** Diethyltryptamine;
- 131 [(s)] **(ff)** Dimethyltryptamine;
- 132 [(t)] **(gg)** 5-methoxy-N,N-diisopropyltryptamine;
- 133 [(u)] **(hh)** Ibogaine;
- 134 [(v)] **(ii)** Lysergic acid diethylamide;
- 135 [(w)] **(jj)** Marijuana or marihuana;
- 136 [(x)] **(kk)** Mescaline;
- 137 [(y)] **(ll)** Parahexyl;
- 138 [(z)] **(mm)** Peyote, to include all parts of the plant presently classified botanically as
139 Lophophora Williamsii Lemaire, whether growing or not; the seeds thereof; any extract from any
140 part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of
141 the plant, its seed or extracts;
- 142 [(aa)] **(nn)** **Benzulpiperazine**;
- 143 **(oo)** N-ethyl-3-piperidyl benzilate;
- 144 [(bb)] **(pp)** N-methyl-3-piperidyl benzilate;
- 145 [(cc)] **(qq)** Psilocybin;
- 146 [(dd)] **(rr)** Psilocyn;
- 147 [(ee)] **(ss)** Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis
148 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis
149 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their
150 isomers with similar chemical structure and pharmacological activity to those substances
151 contained in the plant, such as the following:
- 152 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 153 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 154 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 155 d. Any compounds of these structures, regardless of numerical designation of atomic
156 positions covered;
- 157 [(ff)] **(tt)** Ethylamine analog of phencyclidine;
- 158 [(gg)] **(uu)** Pyrrolidine analog of phencyclidine;
- 159 [(hh)] **(vv)** Thiophene analog of phencyclidine;
- 160 [(ii)] **(ww)** 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;

- 161 [(jj)] (xx) *Salvia divinorum*;
162 [(kk)] (yy) Salvinorin A;
163 [(ll)] (zz) Synthetic cannabinoids:
164 a. Any compound structurally derived from 3-(1-naphthoyl)indole or
165 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by
166 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl
167 [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-**
168 **morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether or not further
169 substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any
170 extent. Including, but not limited to:
171 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
172 (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
173 (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
174 (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
175 (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
176 (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
177 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
178 (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;
179 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
180 (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
181 (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
182 (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
183 (xiii) **(1-Pentyl-1H-Indol-3-YL)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);**
184 **(xiv) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA, AKB48);**
185 **(xv) [1-(5-fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone(5-**
186 **fluoro-UR-144, XLR11);**
187 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the
188 nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
189 1-(N-methyl-2-piperidinyl)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidinyl)**
190 **methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether
191 or not further substituted in the pyrrole ring to any extent, whether or not substituted in the
192 naphthyl ring to any extent;
193 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution
194 at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
195 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**
196 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**

197 group, whether or not further substituted in the indene ring to any extent, whether or not
198 substituted in the naphthyl ring to any extent;

199 d. Any compound structurally derived from 3-phenylacetylindole by substitution at the
200 nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
201 1-(N-methyl-2-piperidiny)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**
202 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**
203 group, whether or not further substituted in the indole ring to any extent, whether or not
204 substituted in the phenyl ring to any extent. Including, but not limited to:

- 205 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
206 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
207 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
208 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
209 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;

210 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by
211 substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
212 cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**
213 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**
214 group, whether or not substituted in the cyclohexyl ring to any extent. Including, but not limited
215 to:

- 216 (i) CP 47, 497 & homologues, or 2-[(1R,3S)-3- hydroxycyclohexyl]-5-(2-methyloctan-2-
217 yl)phenol), where side chain n=5, and homologues where side chain n=4,6, or 7;

218 f. Any compound containing a 3-(benzoyl)indole structure with substitution at the
219 nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
220 1-(N-methyl-2-piperidiny)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**
221 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**
222 group, whether or not further substituted in the indole ring to any extent and whether or not
223 substituted in the phenyl ring to any extent. Including, but not limited to:

- 224 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
225 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;

226 g. Any compound structurally derived from 1H-indol-3-yl-(2,2,3,3-
227 tetramethylcyclopropyl)-methanone by substitution at the nitrogen atom of the indole ring
228 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
229 piperidiny)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-
230 methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not
231 further substituted in the indole ring to any extent, including, but not limited to:

- 232 (i) UR-144, or (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone;

- 233 (ii) XLR-11, or (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-
234 tetramethylcyclopropyl)methanone;
- 235 h. Any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-
236 adamantoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl,
237 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-
238 (4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
239 morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further
240 substituted in the indole ring to any extent, whether or not substituted in the adamantyl
241 group to any extent, including, but not limited to:
- 242 (i) AM-1248, or 1-(N-methyl-2-piperidinyl)methyl-3-(1-adamantoyl)indole;
- 243 (ii) AB-001, or 1-pentyl-3-(1-adamantoyl)indole;
- 244 i. Any compound structurally derived from N-adamantyl-1H-indole-3-carboxamide
245 by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl,
246 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
247 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
248 or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole
249 ring to any extent, whether or not substituted in the adamantyl group to any extent.
250 Including, but not limited to, 2NE1 or 1-pentyl-N-adamantyl-1H-indole-3-carboxamide;
- 251 j. Any compound structurally derived from the N-adamantyl-1H-indazole-3-
252 carboxamide by substitution at the nitrogen atom of the indazole ring by alkyl, haloalkyl,
253 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
254 morpholinyl)ethyl group, whether or not further substituted in the indazole ring to any
255 extent, whether or not substituted in the adamantyl group to any extent, including, but not
256 limited to, AKB48 or 1-pentyl-N-adamantyl-1H-indazole-3-carboxamide;
- 257 k. Any compound structurally derived from 8-quinolinyl ester-1H-indole-3-
258 carboxylic acid by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl,
259 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
260 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl,
261 or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole
262 ring to any extent, whether or not substituted in the quinoline ring to any extent, including,
263 but not limited to:
- 264 (a) PB-22, or 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid;
- 265 (b) 5-fluoro-PB-22, or 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic
266 acid;
- 267 l. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-
268 2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

269 [h.] **m.** HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
270 6a,7,10,10 a-tetrahydrobenzo[c]chromen-1-ol;

271 [i.] **n.** HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-
272 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

273 [j.] **CP** 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-
274 yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

275 k.] **o.** Dimethylheptylpyran, or DMHP;

276 (5) Any material, compound, mixture or preparation containing any quantity of the
277 following substances having a depressant effect on the central nervous system, including their
278 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of
279 isomers is possible within the specific chemical designation:

280 (a) Gamma-hydroxybutyric acid;

281 (b) Mecloqualone;

282 (c) Methaqualone;

283 (6) Any material, compound, mixture or preparation containing any quantity of the
284 following substances having a stimulant effect on the central nervous system, including their
285 salts, isomers and salts of isomers:

286 (a) Aminorex;

287 (b) N-benzylpiperazine;

288 (c) Cathinone;

289 (d) Fenethylamine;

290 (e) 3-Fluoromethcathinone;

291 (f) 4-Fluoromethcathinone;

292 (g) Mephedrone, or 4-methylmethcathinone;

293 (h) Methcathinone;

294 (i) 4-methoxymethcathinone;

295 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazoline);

296 (k) Methylendioxypropylone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-
297 pyrrolidinyl)-1-pentanone);

298 (l) Methylone, or 3,4-Methylenedioxypropylone;

299 (m) 4-Methyl-alpha-pyrrolidinobutylphenone, or MPBP;

300 (n) N-ethylamphetamine;

301 (o) N,N-dimethylamphetamine;

302 (7) A temporary listing of substances subject to emergency scheduling under federal law
303 shall include any material, compound, mixture or preparation which contains any quantity of the
304 following substances:

305 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,
306 salts and salts of isomers;

307 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its
308 optical isomers, salts and salts of isomers;

309 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,
310 whether growing or not; the seeds thereof; any extract from any part of such plant; and every
311 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.

312 3. The department of health and senior services shall place a substance in Schedule II
313 if it finds that:

314 (1) The substance has high potential for abuse;

315 (2) The substance has currently accepted medical use in treatment in the United States,
316 or currently accepted medical use with severe restrictions; and

317 (3) The abuse of the substance may lead to severe psychic or physical dependence.

318 4. The controlled substances listed in this subsection are included in Schedule II:

319 (1) Any of the following substances whether produced directly or indirectly by extraction
320 from substances of vegetable origin, or independently by means of chemical synthesis, or by
321 combination of extraction and chemical synthesis:

322 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or
323 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,
324 nalmefene, naloxone and naltrexone, and their respective salts but including the following:

325 a. Raw opium;

326 b. Opium extracts;

327 c. Opium fluid;

328 d. Powdered opium;

329 e. Granulated opium;

330 f. Tincture of opium;

331 g. Codeine;

332 h. Ethylmorphine;

333 i. Etorphine hydrochloride;

334 j. Hydrocodone;

335 k. Hydromorphone;

336 l. Metopon;

337 m. Morphine;

338 n. Oxycodone;

339 o. Oxymorphone;

340 p. Thebaine;

- 341 **r. Oripavine;**
342 **s. Dihydroetorphine;**
343 (b) Any salt, compound, derivative, or preparation thereof which is chemically
344 equivalent or identical with any of the substances referred to in this subdivision, but not
345 including the isoquinoline alkaloids of opium;
346 (c) Opium poppy and poppy straw;
347 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
348 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
349 with any of these substances, but not including decocainized coca leaves or extractions which
350 do not contain cocaine or ecgonine;
351 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
352 or powder form which contains the phenanthrene alkaloids of the opium poppy);
353 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
354 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
355 the specific chemical designation, dextrorphan and levopropoxyphene excepted:
356 (a) Alfentanil;
357 (b) Alphaprodine;
358 (c) Anileridine;
359 (d) Bezitramide;
360 (e) Bulk dextropropoxyphene;
361 (f) Carfentanil;
362 (g) Dihydrocodeine;
363 (h) Diphenoxylate;
364 (i) Fentanyl;
365 (j) Isomethadone;
366 (k) Levo-alphacetylmethadol;
367 (l) Levomethorphan;
368 (m) Levorphanol;
369 (n) Metazocine;
370 (o) Methadone;
371 (p) Meperidine;
372 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
373 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic
374 acid;
375 (s) Pethidine (meperidine);
376 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;

- 377 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
378 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
379 (w) Phenazocine;
380 (x) Piminodine;
381 (y) Racemethorphan;
382 (z) Racemorphan;
383 (aa) Remifentanyl;
384 (bb) Sufentanyl;
385 (cc) Tapentadol;
386 (3) Any material, compound, mixture, or preparation which contains any quantity of the
387 following substances having a stimulant effect on the central nervous system:
388 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
389 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
390 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
391 (d) Phenmetrazine and its salts;
392 (e) Methylphenidate;
393 (4) Any material, compound, mixture, or preparation which contains any quantity of the
394 following substances having a depressant effect on the central nervous system, including its salts,
395 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers
396 is possible within the specific chemical designation:
397 (a) Amobarbital;
398 (b) Glutethimide;
399 (c) Pentobarbital;
400 (d) Phencyclidine;
401 (e) Secobarbital;
402 (5) Any material or compound which contains any quantity of nabilone;
403 (6) Any material, compound, mixture, or preparation which contains any quantity of the
404 following substances:
405 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
406 (b) Immediate precursors to phencyclidine (PCP):
407 a. 1-phenylcyclohexylamine;
408 b. 1-piperidinocyclohexanecarbonitrile (PCC);
409 **c. Immediate precursor to fentanyl: (ANPP) or 4-anilino-n-phenethyl-4-piperidine;**
410 (7) Any material, compound, mixture, or preparation which contains any quantity of the
411 following alkyl nitrites:
412 (a) Amyl nitrite;

- 413 (b) Butyl nitrite.
- 414 5. The department of health and senior services shall place a substance in Schedule III
415 if it finds that:
- 416 (1) The substance has a potential for abuse less than the substances listed in Schedules
417 I and II;
- 418 (2) The substance has currently accepted medical use in treatment in the United States;
419 and
- 420 (3) Abuse of the substance may lead to moderate or low physical dependence or high
421 psychological dependence.
- 422 6. The controlled substances listed in this subsection are included in Schedule III:
- 423 (1) Any material, compound, mixture, or preparation which contains any quantity of the
424 following substances having a potential for abuse associated with a stimulant effect on the
425 central nervous system:
- 426 (a) Benzphetamine;
427 (b) Chlorphentermine;
428 (c) Clortermine;
429 (d) Phendimetrazine;
- 430 (2) Any material, compound, mixture or preparation which contains any quantity or salt
431 of the following substances or salts having a depressant effect on the central nervous system:
- 432 (a) Any material, compound, mixture or preparation which contains any quantity or salt
433 of the following substances combined with one or more active medicinal ingredients:
- 434 a. Amobarbital;
435 b. Secobarbital;
436 c. Pentobarbital;
- 437 (b) Any suppository dosage form containing any quantity or salt of the following:
- 438 a. Amobarbital;
439 b. Secobarbital;
440 c. Pentobarbital;
- 441 (c) Any substance which contains any quantity of a derivative of barbituric acid or its
442 salt;
- 443 (d) Chlorhexadol;
444 (e) Embutramide;
- 445 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in
446 a drug product for which an application has been approved under Section 505 of the federal
447 Food, Drug, and Cosmetic Act;
- 448 (g) Ketamine, its salts, isomers, and salts of isomers;

- 449 (h) Lysergic acid;
450 (i) Lysergic acid amide;
451 (j) Methypylon;
452 (k) **Perampanel**;
453 (l) Sulfondiethylmethane;
454 [(l)] (m) Sulfonethylmethane;
455 [(m)] (n) Sulfonmethane;
456 [(n)] (o) Tiletamine and zolazepam or any salt thereof;
457 (3) Nalorphine;
458 (4) Any material, compound, mixture, or preparation containing limited quantities of any
459 of the following narcotic drugs or their salts:
460 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
461 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid
462 of opium;
463 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than
464 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized
465 therapeutic amounts;
466 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
467 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an
468 isoquinoline alkaloid of opium;
469 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters
470 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic
471 ingredients in recognized therapeutic amounts;
472 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more
473 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in
474 recognized therapeutic amounts;
475 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters
476 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic
477 ingredients in recognized therapeutic amounts;
478 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per
479 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more
480 active nonnarcotic ingredients in recognized therapeutic amounts;
481 (h) Not more than fifty milligrams of morphine per one hundred milliliters or per one
482 hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic
483 amounts;

(5) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

(6) Anabolic steroids. Any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for that administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subdivision. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers:

- (a) $3\beta,17$ -dihydroxy- 5α -androstane;
- (b) $3\alpha,17\beta$ -dihydroxy- 5α -androstane;
- (c) 5α -androstan- $3,17$ -dione;
- (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy- 5α -androst-1-ene);
- (e) 1-androstenediol ($3\alpha,17\beta$ -dihydroxy- 5α -androst-1-ene);
- (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
- (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
- (h) 1-androstenedione ($[5\alpha]$ -androst-1-en- $3,17$ -dione);
- (i) 4-androstenedione (androst-4-en- $3,17$ -dione);
- (j) 5-androstenedione (androst-5-en- $3,17$ -dione);
- (k) Bolasterone ($7\alpha,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
- (l) Boldenone (17β -hydroxyandrost-1,4,-diene-3-one);
- (m) Boldione;
- (n) Calusterone ($7\beta,17\alpha$ -dimethyl- 17β -hydroxyandrost-4-en-3-one);
- (o) Clostebol (4-chloro- 17β -hydroxyandrost-4-en-3-one);
- (p) Dehydrochloromethyltestosterone (4-chloro- 17β -hydroxy- 17α -methyl-androst-1,4-dien-3-one);
- (q) Desoxymethyltestosterone;
- (r) $\Delta 1$ -dihydrotestosterone (a.k.a. '1-testosterone')(17β -hydroxy- 5α -androst-1-en-3-one);
- (s) 4-dihydrotestosterone (17β -hydroxy-androstan-3-one);
- (t) Drostanolone (17β -hydroxy- 2α -methyl- 5α -androstan-3-one);
- (u) Ethylestrenol (17α -ethyl- 17β -hydroxyestr-4-ene);
- (v) Fluoxymesterone (9-fluoro- 17α -methyl- $11\beta,17\beta$ -dihydroxyandrost-4-en-3-one);
- (w) Formebolone (2-formyl- 17α -methyl- $11\alpha,17\beta$ -dihydroxyandrost-1,4-dien-3-one);

- 520 (x) Furazabol (17 α -methyl-17 β -hydroxyandrostando[2,3-c]-furan);
- 521 (y) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
- 522 (z) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
- 523 (aa) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
- 524 (bb) Mestanolone (17 α -methyl-17 β -hydroxy-5-androstan-3-one);
- 525 (cc) Mesterolone (1 α -methyl-17 β -hydroxy-[5 α]-androstan-3-one);
- 526 (dd) Methandienone (17 α -methyl-17 β -hydroxyandrost-1,4-dien-3-one);
- 527 (ee) Methandriol (17 α -methyl-3 β ,17 β -dihydroxyandrost-5-ene);
- 528 (ff) **Methasterone (2 α -17 α -dimethyl-5 α -androstan-17 β -ol-3-one);**
- 529 (gg) Methenolone (1-methyl-17 β -hydroxy-5 α -androst-1-en-3-one);
- 530 [(gg)] (hh) 17 α -methyl-3 β ,17 β -dihydroxy-5 α -androstande);
- 531 [(hh)] (ii) 17 α -methyl-3 α ,17 β -dihydroxy-5 α -androstande);
- 532 [(ii)] (jj) 17 α -methyl-3 β ,17 β -dihydroxyandrost-4-ene;
- 533 [(jj)] (kk) 17 α -methyl-4-hydroxynandrolone (17 α -methyl-4-hydroxy-17 β -hydroxyestr-4-
- 534 en-3-one);
- 535 [(kk)] (ll) Methyldienolone (17 α -methyl-17 β -hydroxyestra-4,9(10)-dien-3-one);
- 536 [(ll)] (mm) Methyltrienolone (17 α -methyl-17 β -hydroxyestra-4,9-11-trien-3-one);
- 537 [(mm)] (nn) Methyltestosterone (17 α -methyl-17 β -hydroxyandrost-4-en-3-one);
- 538 [(nn)] (oo) Mibolerone (7 α ,17 α -dimethyl-17 β -hydroxyestr-4-en-3-one);
- 539 [(oo)] (pp) 17 α -methyl- Δ 1-dihydrotestosterone (17 β -hydroxy-17 α -methyl-5 α -androst-
- 540 1-en-3-one) (a.k.a. '17- α -methyl-1-testosterone');
- 541 [(pp)] (qq) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
- 542 [(qq)] (rr) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
- 543 [(rr)] (ss) 19-nor-4-androstenediol (3 α ,17 β -dihydroxyestr-4-ene);
- 544 [(ss)] (tt) 19-nor-4,9(10)-androstadienedione;
- 545 [(tt)] (uu) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
- 546 [(uu)] (vv) 19-nor-5-androstenediol (3 α ,17 β -dihydroxyestr-5-ene);
- 547 [(vv)] (ww) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 548 [(ww)] (xx) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 549 [(xx)] (yy) Norbolethone (13 β ,17 α -diethyl-17 β -hydroxygon-4-en-3-one);
- 550 [(yy)] (zz) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
- 551 [(zz)] (aaa) Norethandrolone (17 α -ethyl-17 β -hydroxyestr-4-en-3-one);
- 552 [(aaa)] (bbb) Normethandrolone (17 α -methyl-17 β -hydroxyestr-4-en-3-one);
- 553 [(bbb)] (ccc) Oxandrolone (17 α -methyl-17 β -hydroxy-2-oxa-[5 α]-androstan-3-one);
- 554 [(ccc)] (ddd) Oxymesterone (17 α -methyl-4,17 β -dihydroxyandrost-4-en-3-one);

555 [(ddd)] (eee) Oxymethalone (17a-methyl-2-hydroxymethylene-17 β -hydroxy-[5 α]-
556 androstan-3-one);
557 [(eee)] (fff) **Prostanazol (17 β -hydroxy-5 α -androstan(3,2-c)pyrazole;**
558 **(ggg) Stanazolol** (17 α -methyl-17 β -hydroxy-[5 α]-androst-2-eno[3,2-c]-pyrazole);
559 [(fff)] (hhh) Stenbolone (17 β -hydroxy-2-methyl-[5 α]-androst-1-en-3-one);
560 [(ggg)] (iii) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid
561 lactone);
562 [(hhh)] (jjj) Testosterone (17 β -hydroxyandrost-4-en-3-one);
563 [(iii)] (kkk) Tetrahydrogestrinone (13 β ,17 α -diethyl-17 β -hydroxygon-4,9,11-trien-3-one);
564 [(jjj)] (lll) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
565 [(kkk)] (mmm) Any salt, ester, or ether of a drug or substance described or listed in this
566 subdivision, except an anabolic steroid which is expressly intended for administration through
567 implants to cattle or other nonhuman species and which has been approved by the Secretary of
568 Health and Human Services for that administration;
569 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
570 United States Food and Drug Administration approved drug product;
571 (8) The department of health and senior services may except by rule any compound,
572 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions
573 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to
574 195.320 if the compound, mixture, or preparation contains one or more active medicinal
575 ingredients not having a stimulant or depressant effect on the central nervous system, and if the
576 admixtures are included therein in combinations, quantity, proportion, or concentration that
577 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on
578 the central nervous system.
579 7. The department of health and senior services shall place a substance in Schedule IV
580 if it finds that:
581 (1) The substance has a low potential for abuse relative to substances in Schedule III;
582 (2) The substance has currently accepted medical use in treatment in the United States;
583 and
584 (3) Abuse of the substance may lead to limited physical dependence or psychological
585 dependence relative to the substances in Schedule III.
586 8. The controlled substances listed in this subsection are included in Schedule IV:
587 (1) Any material, compound, mixture, or preparation containing any of the following
588 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
589 as set forth below:

590 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms
591 of atropine sulfate per dosage unit;

592 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-
593 propionoxybutane);

594 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall
595 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer
596 upon the compound, mixture or preparation valuable medicinal qualities other than those
597 possessed by the narcotic drug alone:

598 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per
599 one hundred grams;

600 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters
601 or per one hundred grams;

602 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters
603 or per one hundred grams;

604 (2) Any material, compound, mixture or preparation containing any quantity of the
605 following substances, including their salts, isomers, and salts of isomers whenever the existence
606 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

607 (a) **Alfaxalone**;

608 (b) Alprazolam;

609 [(b)] (c) Barbitol;

610 [(c)] (d) Bromazepam;

611 [(d)] (e) Camazepam;

612 [(e)] (f) **Carisoprodol**;

613 (g) Chloral betaine;

614 [(f)] (h) Chloral hydrate;

615 [(g)] (i) Chlordiazepoxide;

616 [(h)] (j) Clobazam;

617 [(i)] (k) Clonazepam;

618 [(j)] (l) Clorazepate;

619 [(k)] (m) Clotiazepam;

620 [(l)] (n) Cloxazolam;

621 [(m)] (o) Delorazepam;

622 [(n)] (p) Diazepam;

623 [(o)] (q) Dichloralphenazone;

624 [(p)] (r) Estazolam;

625 [(q)] (s) Ethchlorvynol;

626 [(r)] **(t)** Ethinamate;
627 [(s)] **(u)** Ethyl loflazepate;
628 [(t)] **(v)** Fludiazepam;
629 [(u)] **(w)** Flunitrazepam;
630 [(v)] **(x)** Flurazepam;
631 [(w)] **(y)** Fospropofol;
632 [(x)] **(z)** Halazepam;
633 [(y)] **(aa)** Haloxazolam;
634 [(z)] **(bb)** Ketazolam;
635 [(aa)] **(cc)** Loprazolam;
636 [(bb)] **(dd)** Lorazepam;
637 [(cc)] **(ee)** **Lorcaserin**;
638 **(ff)** Lormetazepam;
639 [(dd)] **(gg)** Mebutamate;
640 [(ee)] **(hh)** Medazepam;
641 [(ff)] **(ii)** Meprobamate;
642 [(gg)] **(jj)** Methohexital;
643 [(hh)] **(kk)** Methylphenobarbital (mephobarbital);
644 [(ii)] **(ll)** Midazolam;
645 [(jj)] **(mm)** Nimetazepam;
646 [(kk)] **(nn)** Nitrazepam;
647 [(ll)] **(oo)** Nordiazepam;
648 [(mm)] **(pp)** Oxazepam;
649 [(nn)] **(qq)** Oxazolam;
650 [(oo)] **(rr)** Paraldehyde;
651 [(pp)] **(ss)** Petrichloral;
652 [(qq)] **(tt)** Phenobarbital;
653 [(rr)] **(uu)** Pinazepam;
654 [(ss)] **(vv)** Prazepam;
655 [(tt)] **(ww)** Quazepam;
656 [(uu)] **(xx)** Temazepam;
657 [(vv)] **(yy)** Tetrazepam;
658 [(ww)] **(zz)** Triazolam;
659 [(xx)] **(aaa)** Zaleplon;
660 [(yy)] **(bbb)** Zolpidem;
661 [(zz)] **(ccc)** Zopiclone;

662 (3) Any material, compound, mixture, or preparation which contains any quantity of the
663 following substance including its salts, isomers and salts of isomers whenever the existence of
664 such salts, isomers and salts of isomers is possible: fenfluramine;

665 (4) Any material, compound, mixture or preparation containing any quantity of the
666 following substances having a stimulant effect on the central nervous system, including their
667 salts, isomers and salts of isomers:

- 668 (a) Cathine ((+)-norpseudoephedrine);
- 669 (b) Diethylpropion;
- 670 (c) Fencamfamin;
- 671 (d) Fenproporex;
- 672 (e) Mazindol;
- 673 (f) Mefenorex;
- 674 (g) Modafinil;
- 675 (h) Pemoline, including organometallic complexes and chelates thereof;
- 676 (i) Phentermine;
- 677 (j) Pipradrol;
- 678 (k) Sibutramine;
- 679 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

680 (5) Any material, compound, mixture or preparation containing any quantity of the
681 following substance, including its salts:

- 682 (a) butorphanol;
- 683 (b) pentazocine;

684 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance
685 is the only active medicinal ingredient;

686 (7) The department of health and senior services may except by rule any compound,
687 mixture, or preparation containing any depressant substance listed in subdivision (1) of this
688 subsection from the application of all or any part of sections 195.010 to 195.320 if the
689 compound, mixture, or preparation contains one or more active medicinal ingredients not having
690 a depressant effect on the central nervous system, and if the admixtures are included therein in
691 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the
692 substances which have a depressant effect on the central nervous system.

693 9. The department of health and senior services shall place a substance in Schedule V
694 if it finds that:

695 (1) The substance has low potential for abuse relative to the controlled substances listed
696 in Schedule IV;

697 (2) The substance has currently accepted medical use in treatment in the United States;
698 and

699 (3) The substance has limited physical dependence or psychological dependence liability
700 relative to the controlled substances listed in Schedule IV.

701 10. The controlled substances listed in this subsection are included in Schedule V:

702 (1) Any compound, mixture or preparation containing any of the following narcotic
703 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set
704 forth below, which also contains one or more nonnarcotic active medicinal ingredients in
705 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal
706 qualities other than those possessed by the narcotic drug alone:

707 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than
708 twenty-five micrograms of atropine sulfate per dosage unit;

709 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per
710 one hundred grams;

711 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five
712 micrograms of atropine sulfate per dosage unit;

713 (2) Any material, compound, mixture or preparation which contains any quantity of the
714 following substance having a stimulant effect on the central nervous system including its salts,
715 isomers and salts of isomers: pyrovalerone;

716 (3) Any compound, mixture, or preparation containing any detectable quantity of
717 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,
718 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical
719 isomers, or salts of optical isomers;

720 (4) Unless specifically exempted or excluded or unless listed in another schedule, any
721 material, compound, mixture, or preparation which contains any quantity of the following
722 substances having a depressant effect on the central nervous system, including its salts:

723 (a) **Ezogabine;**

724 (b) **Lacosamide;**

725 [(b)] (c) **Pregabalin.**

726 11. If any compound, mixture, or preparation as specified in subdivision (3) of
727 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a
728 prescription:

729 (1) All packages of any compound, mixture, or preparation containing any detectable
730 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,
731 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind

732 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or
733 registered pharmacy technician; and

734 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,
735 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,
736 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers
737 shall be at least eighteen years of age; and

738 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require
739 any person, [prior to their] **before such person's** purchasing, receiving or otherwise acquiring
740 such compound, mixture, or preparation to furnish suitable photo identification that is issued by
741 a state or the federal government or a document that, with respect to identification, is considered
742 acceptable and showing the date of birth of the person;

743 (4) The seller shall deliver the product directly into the custody of the purchaser.

744 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall
745 implement and maintain an electronic log of each transaction. Such log shall include the
746 following information:

747 (1) The name, address, and signature of the purchaser;

748 (2) The amount of the compound, mixture, or preparation purchased;

749 (3) The date and time of each purchase; and

750 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy
751 technician who dispensed the compound, mixture, or preparation to the purchaser.

752 13. Each pharmacy shall submit information regarding sales of any compound, mixture,
753 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with
754 transmission methods and frequency established by the department by regulation;

755 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities
756 greater than those specified in this chapter.

757 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products
758 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter
759 where the public is not permitted.

760 16. Any person who knowingly or recklessly violates the provisions of subsections 11
761 to 15 of this section is guilty of a class A misdemeanor.

762 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this
763 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,
764 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,
765 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must
766 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

767 18. The manufacturer of a drug product or another interested party may apply with the
768 department of health and senior services for an exemption from this section. The department of
769 health and senior services may grant an exemption by rule from this section if the department
770 finds the drug product is not used in the illegal manufacture of methamphetamine or other
771 controlled or dangerous substances. The department of health and senior services shall rely on
772 reports from law enforcement and law enforcement evidentiary laboratories in determining if the
773 proposed product can be used to manufacture illicit controlled substances.

774 19. The department of health and senior services shall revise and republish the schedules
775 annually.

776 20. The department of health and senior services shall promulgate rules under chapter
777 536 regarding the security and storage of Schedule V controlled substances, as described in
778 subdivision (3) of subsection 10 of this section, for distributors as registered by the department
779 of health and senior services.

780 21. Logs of transactions required to be kept and maintained by this section and section
781 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is
782 the person whose transactions are recorded in the logs.

✓